

Glenmark receives final ANDA approval for Desoximetasone Ointment USP, 0.25%

30 November -0001 | News | By BioSpectrum Bureau

Glenmark receives final ANDA approval for Desoximetasone Ointment USP, 0.25%



Glenmark Generics Inc. , USA the subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approval (ANDA) from the United States and Drug Administration (U.S FDA) for Desoximetasone Ointment USP, 0.25% their generic version of Topicort by taro Pharmaceuticals USA Inc and shipping will commence immediately.

Desoximetasone Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Glenmarks current portfolio consists of 89 products authorized for distribution in the U.S marketplace and 54 ANDA's pending approval with the U.S FDA. in addition to these internal filings, GGI continues to identify and partnership to supplement and accelerate the growth of the existing pipeline and portfolio.